Efavirenz-induced neurological symptoms in rare homozygote CYP2B6*2/*2 (C64T)

被引:8
|
作者
Usami, Osamu
Ashino, Yugo
Komaki, Yuichi
Tomaki, Masafurni
Irokawa, Toshiya
Tamada, Tsutornu
Hayashida, Tsunefusa
Teruya, Katsuji
Hattori, Toshio
机构
[1] Tohoku Univ, Div Infect & Resp Dis, Aoba Ku, Sendai, Miyagi 980, Japan
[2] Int Med Ctr Japan, AIDS Clin Ctr, Tokyo, Japan
关键词
polymorphism; SNP; HIV; HAART; Japan; REVERSE-TRANSCRIPTASE INHIBITOR; CYTOCHROME P4502B6 GENE; ALLELE FREQUENCIES; CYP2B6; METABOLISM; PHARMACOKINETICS; VARIABILITY; THERAPY;
D O I
10.1258/095646207781439810
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Some of the HIV-1 -infected patients who were given highly active anti-retroviral therapy (HAART) including efavirenz (EFV) presented adverse central nervous system (CNS) symptoms such as fatigue and insomnia. The incidence of adverse CNS symptoms is associated with hepatic cytochrome P450 isozymes (CYP2B6) polymorphisms. For example, CYP2B6 *6 (G516T and A785G) and *7 (G516T, A785G and C1459T) prolonged the EFV half-life despite discontinuation of EFV. CYP2B6 *2/*2 (C641) is extremely rare and there have been no data describing the EFV plasma concentrations in C64T homozygous patients, who developed adverse CNS symptoms. C64T homozygous possibly has some catalytic defects.
引用
收藏
页码:575 / 576
页数:2
相关论文
共 50 条
  • [1] Efavirenz-induced neurological symptoms in rare homozygote CYP2B6 *2/*2 (C64T) (vol 18, pg 575, 2007)
    Usami, O.
    Ashino, Y.
    Komaki, Y.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2007, 18 (10) : 726 - 726
  • [2] ASSOCIATION OF THE CYP2B6*6 ALLELE WITH EFAVIRENZ-INDUCED QT INTERVAL CHANGES AT STEADY STATE IN HEALTHY SUBJECTS
    Abdelhady, A. M.
    Thong, N.
    Kreutz, Y.
    Tisdale, J. E.
    Desta, Z.
    Overholser, B. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S22 - S23
  • [3] CYP2B6 GENETIC VARIATION AND EFAVIRENZ AUTOINDUCTION INFLUENCES CYP2B6 A ACTIVITY AND EFAVIRENZ EXPOSURE IN HEALTHY VOLUNTEERS
    Metzger, I. F.
    Lu, J. B.
    Kreutz, Y.
    Thong, N.
    Flockhart, D. A.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S80 - S80
  • [5] Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog
    Shah, Manish B.
    Zhang, Qinghai
    Halpert, James R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (04)
  • [6] Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo
    Xu, Cong
    Ogburn, Evan T.
    Guo, Yingying
    Desta, Zeruesenay
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 717 - 725
  • [7] CYP2B6 18492T→C Polymorphism Compromises Efavirenz Concentration in Coinfected HIV and Tuberculosis Patients Carrying CYP2B6 Haplotype*1/*1
    Manosuthi, Weerawat
    Sukasem, Chonlaphat
    Thongyen, Supeda
    Nilkamhang, Samruay
    Manosuthi, Sukanya
    Sungkanuparph, Somnuek
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (04) : 2268 - 2273
  • [8] Efavirenz intoxication due to a new CYP2B6 constellation
    Anagnostopoulos, Alexia
    Rotger, Margalida
    Aouri, Manel
    Kuster, Stefan P.
    Telenti, Amalio
    Decosterd, Laurent A.
    Guenthard, Huldrych F.
    ANTIVIRAL THERAPY, 2013, 18 (05) : 739 - 743
  • [9] Allelic and Genotype Frequencies of CYP2B6*2 (64C > T) and CYP2B6*3 (777C > A) in Three Dominant Ethnicities of the Iranian Population
    Khavandegar, Armin
    Tavakoli-Far, Bahareh
    Ansari, Sarina
    Veis-Karami, Parisa
    Ghasemi, Faezeh
    Sheibaninia, Samira
    Jazayeri, Roshanak
    Houshmand, Massoud
    GENETICS RESEARCH, 2023, 2023
  • [10] Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry
    Wang, Pan-Fen
    Neiner, Alicia
    Kharasch, Evan D.
    DRUG METABOLISM AND DISPOSITION, 2019, 47 (10) : 1195 - 1205